calcineurin inhibitor

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

Drug interactions

Mechanism of action

More general terms

More specific terms

Additional terms

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
  2. Moes AD, Hesselink DA, Zietse R et al Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014 Jun;15(9):1243-51. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25141899
  3. 3.0 3.1 Asgari MM et al. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 2020 Aug 12; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32785626 https://jamanetwork.com/journals/jamadermatology/fullarticle/2768937
  4. 4.0 4.1 Lam M, Zhu JW, Tadrous M et al Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma. A Systematic Review and Meta-analysis. JAMA Dermatol. Published online March 31, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33787818 https://jamanetwork.com/journals/jamadermatology/fullarticle/2778024